BioStock: Iconovo’s oxytocin treatment in clinical phase I study

Postpartum haemorrhage is the leading cause of maternal mortality globally, especially in developing countries. Monash University is collaborating with Iconovo to develop an inhalable, preventive oxytocin treatment that aims to provide effective protection against these bleedings. Iconovo was recently able to announce that Monash has started a clinical phase I study with the treatment in Melbourne. In addition, the product is featured in Designing Motherhood, an international design exhibition. Måns Österberg at Iconovo tells us more about the project.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/05/iconovos-oxytocin-treatment-in-clinical-phase-i-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se